Amersham and GeneBio Expand 2D Gel Software Alliance
Amersham Biosciences and Geneva Bioinformatics have signed an exclusive proteomics software agreement, the two companies said this week.
GeneBio’s Melanie 2D gel analysis software, which is developed by the Swiss Institute of Bioinformatics, will be integrated into Amersham’s ImageMaster image analysis software platform and will be available upon its next release.
The companies also plan to develop further imaging software collaboratively.
The new agreement expands a strategic alliance to develop and distribute novel proteomics analysis software, databases, and training tools that Amersham and GeneBio announced in January (see PM 1-13-03).
Caprion and Wyeth Pen Biomarker Collaboration
Caprion Pharmaceuticals and Wyeth have started a collaboration to identify biomarkers, the companies said this week.
Under the agreement, Caprion will study the effect of pharmaceutical compounds from Wyeth on plasma proteins in a preclinical model of inflammation, using its CellCarta proteomics discovery platform.
The companies hope to learn about the mechanism of action of these compounds and to be able to optimize their action.
Tecan US and EMD Biosciences Sign Co-Marketing Agreement
Tecan US of Research Triangle Park, N.C., and EMD Biosciences of Madison, Wis., have agreed to co-market a number of products for protein extraction, screening, and purification, the companies said this week.
EMD, an affiliate of Darmstadt, Germany-based Merck, provides reagents for molecular biology and proteomics through its Novagen brand. The two companies will combine Tecan’s automated platforms for recombinant protein purification with Novagen’s reagent kits. As part of the collaboration, they formed a technical applications team that will provide technical support.
Agilent and Battelle to Develop Protein ID Software
Agilent Technologies has signed a Cooperative Research and Development Agreement with Battelle Memorial Institute, the operating and management contractor for the DOE’s Pacific Northwest National Laboratory, the company said this week.
The goal of the collaboration is to further develop an artificial neural network technology for protein identification that was developed by Richard Smith at PNNL, and to adapt it to Agilent’s LC/MS systems.
The technology predicts how long it takes individual peptides to elute from a liquid chromatograph. This increases the confidence in the identification of peptides and the proteins from which they are derived.
Agilent will supply its LC/MS platform to PNNL, which plans to use DOE funding to demonstrate the peptide retention time capability on these instruments. Under the CRADA, Agilent has the option to negotiate an exclusive license for the patent-pending IP, and for any inventions that may result from the collaboration.
Astex Solves First Human CYP450 Structure, Opens New Research Facility
Astex Technology of Cambridge, UK, has published the first three-dimensional crystal structure of a human cytochrome P450 protein, the company said this week.
The structure of the protein, CYP450 2C9 — in the absence and presence of the anticoagulant warfarin — was published online in Nature on July 13. CYP450 2C9 is one of four enzymes that are responsible for metabolizing more than 90 percent of drugs. Astex has filed patents on the use of the crystal structure and is now sharing this information with a number of pharmaceutical partners.
Last week, Astex opened a new, 36,000-square-foot research and development facility at Cambridge Science Park, which will house up to 150 research scientists, and which can be extended by another 30,000 square feet.
Waters Associates To Pay $6.5M
Waters Associates, a subsidiary of Waters, is settling an air and water pollution complaint for $6.5 million, according to a newspaper report.
Last week, the Herald News of Fall River, Mass., reported that Waters Associates, located in the Myles Standish Industrial Park of Taunton, Mass., is settling the complaint, filed by state attorney general Tom Reilly. According to the news report, the company was accused of increasing its airborne emissions after changing production procedures and of filing incorrect data on airborne emissions for 20 years. It also allegedly discharged contaminated water without the proper permits.